[TNBC, stage IV: a patient's journey, from standard options to the new era of ADC.]

Triple-negative breast cancer (TNBC) continues to be the most aggressive molecular subtype of breast cancer and the optimal therapeutic management is still a challenge. Due to the lack of "traditional" molecular targets, for decades, systemic treatment has been characterized by the use of classic cytotoxic drugs. In recent years, it has been proved that TNBC is not represented by a single pathology lack of specific features, but of different entities with distinct genetic, histological and clinical alterations. This allowed to optimize and improve the therapeutic management of the disease, with the approval of multiple anti-tumor agents, including antibody-drug conjugates (ADC). The clinical case we present illustrates the "journey" of a patient affected by metastatic TNBC, of the therapeutic choices made among the options available over the years, from the standard options to the innovative strategies.